Find LAROPIPRANT manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 571170-77-9, Mk 0524, Mk-0524, Cardaptive, Cordaptive, Chembl426559
Molecular Formula
C21H19ClFNO4S
Molecular Weight
435.9  g/mol
InChI Key
NXFFJDQHYLNEJK-CYBMUJFWSA-N
FDA UNII
G7N11T8O78

LAROPIPRANT
Laropiprant is a prostaglandin D2 receptor (DP1) antagonist with niacin-induced vasodilation inhibiting activity. Laropiprant binds to and inhibits the activity of DP1, a G-protein coupled receptor. Via competing with prostaglandin D2 (PG D2) for binding to DP1, this agent prevents PG D2-induced vasodilation and increased blood flow. As niacin induces the synthesis of PG D2, predominantly in the skin, administration of laropiprant may prevent niacin-induced vasodilation in the skin and facial flushing.
1 2D Structure

LAROPIPRANT

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(3R)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1H-cyclopenta[b]indol-3-yl]acetic acid
2.1.2 InChI
InChI=1S/C21H19ClFNO4S/c1-29(27,28)18-10-15(23)9-17-16-7-4-13(8-19(25)26)20(16)24(21(17)18)11-12-2-5-14(22)6-3-12/h2-3,5-6,9-10,13H,4,7-8,11H2,1H3,(H,25,26)/t13-/m1/s1
2.1.3 InChI Key
NXFFJDQHYLNEJK-CYBMUJFWSA-N
2.1.4 Canonical SMILES
CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CCC3CC(=O)O)CC4=CC=C(C=C4)Cl)F
2.1.5 Isomeric SMILES
CS(=O)(=O)C1=CC(=CC2=C1N(C3=C2CC[C@@H]3CC(=O)O)CC4=CC=C(C=C4)Cl)F
2.2 Other Identifiers
2.2.1 UNII
G7N11T8O78
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl Acetic Acid

2. Mk-0524

2.3.2 Depositor-Supplied Synonyms

1. 571170-77-9

2. Mk 0524

3. Mk-0524

4. Cardaptive

5. Cordaptive

6. Chembl426559

7. G7n11t8o78

8. 2-[(3r)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic Acid

9. ((3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid

10. (-)-((3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta(b)indol-3-yl)acetic Acid

11. 2-[(3r)-4-[(4-chlorophenyl)methyl]-7-fluoro-5-methanesulfonyl-1h,2h,3h,4h-cyclopenta[b]indol-3-yl]acetic Acid

12. Cyclopent(b)indole-3-acetic Acid, 4-((4-chlorophenyl)methyl)-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3r)-

13. Laropiprant [usan]

14. Tedaptive

15. Unii-g7n11t8o78

16. Laropiprant [usan:inn:ban]

17. Cyclopent[b]indole-3-acetic Acid, 4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-5-(methylsulfonyl)-, (3r)-

18. [14c]-laropiprant

19. Laropiprant [mi]

20. Laropiprant [inn]

21. Laropiprant (inn/usan)

22. Laropiprant; Mk-0524

23. Laropiprant (mk-0524)

24. Laropiprant [mart.]

25. Laropiprant [who-dd]

26. Schembl991107

27. Laropiprant [ema Epar]

28. Amot0189

29. Gtpl3356

30. Dtxsid60205756

31. Chebi:135942

32. Bcpp000161

33. Bcp02136

34. Ex-a2099

35. Zinc3961849

36. Bdbm50205275

37. Laropiprant,cas:571170-77-9

38. Mk0524

39. Akos030526850

40. Am81247

41. At34794

42. Bcp9000944

43. Cardaptive; Mk 0524; Mk-0524

44. Cs-0539

45. Db11629

46. Ncgc00345790-10

47. Ac-35835

48. As-17012

49. Hy-50175

50. A25234

51. D08940

52. Q412291

53. [(3r)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid

54. Laropiprant;(r)-2-(4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic Acid

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 435.9 g/mol
Molecular Formula C21H19ClFNO4S
XLogP33.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass435.0707351 g/mol
Monoisotopic Mass435.0707351 g/mol
Topological Polar Surface Area84.8 Ų
Heavy Atom Count29
Formal Charge0
Complexity721
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty